UCLA Wins $25M to Rigorously Test AI Tools for Alzheimer's Diagnosis and Care

Artificial intelligence is entering dementia care faster than the evidence to support it, and a new $25 million federal grant is designed to close that gap. UCLA Health will lead APEX-ADRD, a five-year national program funded by the National Institute on Aging, tasked with systematically evaluating AI tools built to diagnose and treat Alzheimer's disease and related dementias. The program partners with Mayo Clinic and the University of Wisconsin, among other institutions.

The core problem APEX-ADRD addresses is timing. AI products routinely reach clinics before rigorous studies confirm whether they help or harm. In dementia care, where more than 7.2 million Americans are affected and numbers are projected to grow, the stakes of deploying an unreliable tool are especially high. Older adults with dementia, as program co-director Dr. John Mafi noted, have the most to gain and the most to lose.

Rather than functioning as a single lab project, the program is structured as a national testing hub. Evaluation frameworks and safety monitoring standards developed at UCLA will be shared across the NIA network, giving investigators nationwide a common rulebook for assessing AI-powered clinical technologies before broad rollout. Funding will also flow to external research teams, extending the program's reach.

The team plans to evaluate tools across California's diverse population using data from the entire University of California health system, then validate findings across multiple care settings to catch performance gaps that may appear in one patient group but not another. Dr. Joann Elmore summarized the guiding principle plainly: potential is not the same as evidence, and the real measure is whether patient care actually improves.

For health-conscious readers, the practical implication is that AI tools claiming to detect cognitive decline earlier or personalize dementia care plans should be viewed as promising hypotheses until programs like APEX-ADRD provide the evidence. Rigorous, pre-deployment validation is the standard this initiative is trying to establish nationally.